Edesa Biotech licenses paridiprubart to Kyorin in Japan for up to $146 million plus royalties
Edesa Biotech has licensed Japanese development and commercialisation rights to its investigational anti-TLR4 antibody paridiprubart to Kyorin Pharmaceutical in an agreement worth up to $146 million in stated payments plus royalties.
Edesa Biotech and Kyorin Pharmaceutical announced an exclusive collaboration and licence agreement on 9 November 2026 granting Kyorin rights in Japan to develop and commercialise paridiprubart (EB05), an investigational monoclonal antibody targeting TLR4 for acute respiratory distress syndrome.
The agreement includes a $12 million upfront payment, up to $134 million in development, reimbursement-listing and sales-related milestones and royalties on Japanese net sales, while Edesa retains rights outside Japan and manufacturing rights and the product remains investigational rather than approved for ARDS.
Field | Content |
Article Type | Deals |
Licensor | Edesa Biotech |
Licensee | Kyorin Pharmaceutical |
Deal Type | Exclusive regional collaboration and licence agreement |
Announcement Date | 9 November 2026 |
Agreement Status | Announced |
Licensed Product | Paridiprubart |
Development Code | EB05 |
Drug Modality | Monoclonal antibody |
Molecular Target | Toll-like receptor 4 |
Target Abbreviation | TLR4 |
Therapeutic Area | Critical care and inflammatory disease |
Target Indication | Acute respiratory distress syndrome |
Indication Abbreviation | ARDS |
Licensed Territory | Japan |
Licensed Rights | Japanese development and commercialisation |
Rights Retained by Edesa | Rights outside Japan and manufacturing rights |
Upfront Payment | $12 million |
Potential Milestone Payments | Up to $134 million |
Milestone Categories | Development, reimbursement listing and sales |
Maximum Stated Payments | Up to $146 million |
Additional Royalties | Royalties on Japanese net sales |
Royalty Rates | Not disclosed |
Total Potential Economics | Up to $146 million in stated payments plus royalties |
Regulatory Status | Investigational; not approved for ARDS |
Development Stage | Not specified in supplied summary |
Manufacturing Responsibilities | Manufacturing rights retained by Edesa |
Commercial Responsibilities | Kyorin holds Japanese commercialisation rights |
Geographic Scope Outside Japan | Rights retained by Edesa |
What Happened | Edesa granted Kyorin exclusive Japanese development and commercialisation rights to paridiprubart. |
Why It Matters | The agreement provides a regional development and commercialisation partner for an investigational therapy targeting a serious critical-care condition. |
Strategic Significance | Expands the potential Japanese development pathway for paridiprubart while preserving Edesa's rights in other markets. |
Financial Clarification | The $146 million headline includes $134 million of contingent milestones; only $12 million is specified as upfront consideration, with royalties additional. |
Regulatory Clarification | Paridiprubart remains investigational and the licensing agreement does not constitute marketing approval. |
Key Takeaway | Kyorin obtained exclusive Japanese rights to paridiprubart through a $12 million upfront agreement with substantial contingent milestones. |
What to Watch | Japanese development plans, clinical progress, regulatory interactions, milestone achievements and potential commercialisation. |
Primary Source | Kyorin Pharmaceutical |
Primary Source URL | https://www.kyorin-pharm.co.jp/en/news/2026/001956.shtml |
Relevant Date | 9 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
댓글